SHANDONG XINHUA's Subsidiary Obtains Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets

Stock News03-04 16:34

SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets (I) and (III) issued by the National Medical Products Administration. The product, used in conjunction with diet and exercise, is suitable for adult patients with type 2 diabetes who require treatment with saxagliptin and metformin to improve glycemic control. It is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The product is listed as a Category B drug in the National Reimbursement Drug List (2025). According to relevant statistics, sales of saxagliptin and metformin extended-release tablets in China's public medical institutions reached approximately RMB 419 million in 2024. The recent approval of Xinda Pharmaceutical's Saxagliptin and Metformin Extended-Release Tablets (I) and (III) will help enrich the company's portfolio of diabetes treatments and enhance its overall competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162706527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162706527","market":"sg","top_or_hot":-1,"title":"SHANDONG XINHUA's Subsidiary Obtains Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets (I) and (III) issued by the National Medical Products Administration. The product, used in conjunction with diet and exercise, is suitable for adult patients with type 2 diabetes who require treatment with saxagliptin and metformin to improve glycemic control. It is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The product is listed as a Category B drug in the National Reimbursement Drug List (2025). According to relevant statistics, sales of saxagliptin and metformin extended-release tablets in China's public medical institutions reached approximately RMB 419 million in 2024. The recent approval of Xinda Pharmaceutical's Saxagliptin and Metformin Extended-Release Tablets (I) and (III) will help enrich the company's portfolio of diabetes treatments and enhance its overall competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA's Subsidiary Obtains Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA's Subsidiary Obtains Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-04 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets (I) and (III) issued by the National Medical Products Administration. The product, used in conjunction with diet and exercise, is suitable for adult patients with type 2 diabetes who require treatment with saxagliptin and metformin to improve glycemic control. It is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The product is listed as a Category B drug in the National Reimbursement Drug List (2025). According to relevant statistics, sales of saxagliptin and metformin extended-release tablets in China's public medical institutions reached approximately RMB 419 million in 2024. The recent approval of Xinda Pharmaceutical's Saxagliptin and Metformin Extended-Release Tablets (I) and (III) will help enrich the company's portfolio of diabetes treatments and enhance its overall competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1162706527","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162706527","pubTimestamp":1772613261,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"山东新华子公司获得沙格列汀二甲双胍缓释片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets (I) and (III) issued by the National Medical Products Administration. The product, used in conjunction with diet and exercise, is suitable for adult patients with type 2 diabetes who require treatment with saxagliptin and metformin to improve glycemic control. It is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The product is listed as a Category B drug in the National Reimbursement Drug List (2025). According to relevant statistics, sales of saxagliptin and metformin extended-release tablets in China's public medical institutions reached approximately RMB 419 million in 2024. The recent approval of Xinda Pharmaceutical's Saxagliptin and Metformin Extended-Release Tablets (I) and (III) will help enrich the company's portfolio of diabetes treatments and enhance its overall competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162706527","isCrawlerRequest":true}